|
We are currently conducting CNS studies for the treatments of Alzheimer’s Disease (AD), Diabetic Peripheral Neuropathy (DPN), Epilepsy, Multiple Sclerosis (MS), and Parkinson’s Disease (PD).
Please click on the links to the right for more information on our current enrolling studies.
Alzheimer's Disease (ELN301/302):
This research study is for patients 50-88 years of age diagnosed with probable mild to moderate Alzheimer's disease. You must have a caregiver that is willing to be involved in the study. This study lasts 83 weeks with 15 visits. You will receive 6 infusions every 13 weeks. This research study compares the safety and effectiveness of 3 doses of an investigational drug to placebo. The investigational drug is aimed at slowing the progression of the disease. There is no cost to participate and the patient participation is voluntary. There is some reimbursement for time and travel available. Contact Clinical Trials, Inc. at 501-227-6179 to see if you or a loved one might qualify. For email inquiries, contact info@clinicaltrialsinc.com.
Return to the list of our services
Diabetic Neuropathy (PXN):
This research study is for patients 18 years of age and older diagnosed with type 1 or 2 diabetes and experiencing pain due to peripheral neuropathy for at least 6 months and no longer than 5 years. Hemoglobin A1C must be equal to or less than 8%. No investigational drug within 30 days (for other illness) or 6 months (for DPN) and no allergic or adverse reaction to gabapentin (Neurotin), pregabalin (Lyrica) or acetaminophen (Tylenol). This study lasts 20 weeks with visits every 1-4 weeks with up to 9 clinic visits. This research study compares the safety and effectiveness of 3 doses of an investigational drug to pregabalin (Lyrica) and placebo. THIS STUDY IS NO LONGER ENROLLING NEW PATIENTS.
Return to the list of our services
Epilepsy (NO1253):
This study is for patients 16-70 years of age diagnosed with epilepsy with partial-onset seizures with or without secondarily generalization that are uncontrolled despite optimal treatment with 1-2 antiepileptic medications (AEDS). Must experience at least 8 partial seizures during the 8-week baseline period. Use of vagal nerve stimulation (VNS) is allowed if implanted for at least 9 months. Must weigh > 99 lbs and cannot have been previously treated with brivaracetam. This study lasts up to 23 weeks with visits every 2-4 weeks with a total of 8 clinic visits. This study tests the effectiveness of an investigational drug compared to placebo. There is no cost to participate and the patient participation is voluntary. There is some reimbursement for time and travel available. Contact Clinical Trials, Inc. at 501-227-6179 to see if you or a loved one might qualify. For email inquiries, contact info@clinicaltrialsinc.com
Return to the list of our services
Epilepsy (SP902/904):
This study is for patients 16-70 years of age diagnosed with epilepsy with partial-onset seizures with or without secondary generalization. Must be on a stable dose (28 days) of 1 or 2 AED's (anti-epileptic drugs). Must weigh >88lbs and cannot have been in any other trial in the last 2 months. This study lasts up to 30 weeks with visits every 1-4 weeks with a total of up to 14 clinic visits and a possible extension study lasting 2 years. This study tests the effectiveness and safety of an investigational drug as monotherapy (other AEDs will be discontinued). There is no cost to participate and the patient participation is voluntary. There is some reimbursement for time and travel available. Contact Clinical Trials, Inc. at 501-227-6179 to see if you or a loved one might qualify. For email inquiries, contact info@clinicaltrialsinc.com.
Return to the list of our services
Epilepsy (K826):
This research study is for patients ages 2 and older diagnosed with epilepsy experiencing acute repetitive seizures (ARS) that require intermittent medical intervention. The patient must weight more than 13 lbs and no more than 300 lbs. Must be on a stable regimen of AEDs for at least 2 weeks, vagal nerve stimulation (VNS) is allowed if implanted for at least 6 months and stable for 2 weeks. Must have experienced at least 2 episodes of ARS in the last year, one of which must have occurred in the last 6 months. Must have a reliable caregiver that is 18 or older and can administer study drug and monitor patient seizures and respiratory rate (2 hour training provided). The length of this study is up to 18 months, visits are based on frequency of ARS episodes and study drug use. There is no cost to participate and participation is voluntary. There is some reimbursement for time and travel available. Contact Clinical Trials, Inc. at 501-227-6179 to see if you or a loved one might qualify. For email inquiries, contact info@clinicaltrialsinc.com
Return to the list of our services
Epilepsy (NO1280):
This research study is for patients 12-75 years of age diagnosed with epilepsy with partial-onset seizures with secondarily generalization. Must have inadequately controlled partial seizures supported by an EEG and MRI/CT. Must experience 2 to 40 seizures per 4-week period and must be on a stable dose of a maximum of 2 AED(s) for at least 4 weeks. No investigational drug within 4 months and cannot have been previously treated with levetiracetam (Keppra) or have sensitivity to levetiracetam (Keppra). This study lasts 29 weeks with visits every 2-4 weeks with a total of 10-11 clinic visits. This study tests the effectiveness of a new therapy compared with a historical control, in the conversion to monotherapy treatment. There is no cost to participate and the patient participation is voluntary. There is some reimbursement for time and travel available. Contact Clinical Trials, Inc. at 501-227-6179 to see if you or a loved one might qualify. For email inquiries, contact info@clinicaltrialsinc.com
Return to the list of our services
|
